These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25253272)

  • 1. Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.
    Bailey CP; Husbands SM
    Expert Opin Drug Discov; 2014 Nov; 9(11):1333-44. PubMed ID: 25253272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opioid receptors as targets for drug abuse medication.
    Noble F; Lenoir M; Marie N
    Br J Pharmacol; 2015 Aug; 172(16):3964-79. PubMed ID: 25988826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
    Zaveri NT
    Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of opioid receptors in the reinstatement of opioid-seeking behavior: an overview.
    Fattore L; Fadda P; Antinori S; Fratta W
    Methods Mol Biol; 2015; 1230():281-93. PubMed ID: 25293335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review.
    Nicolas C; Zlebnik NE; Farokhnia M; Leggio L; Ikemoto S; Shaham Y
    Pharmacol Rev; 2022 Jan; 74(1):119-140. PubMed ID: 34987089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where do we stand in the field of anti-abuse drug discovery?
    Tzschentke TM
    Expert Opin Drug Discov; 2014 Nov; 9(11):1255-8. PubMed ID: 25162980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
    Xi ZX; Gardner EL
    Curr Drug Abuse Rev; 2008 Nov; 1(3):303-27. PubMed ID: 19430578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.
    Weiss F; Ciccocioppo R; Parsons LH; Katner S; Liu X; Zorrilla EP; Valdez GR; Ben-Shahar O; Angeletti S; Richter RR
    Ann N Y Acad Sci; 2001 Jun; 937():1-26. PubMed ID: 11458532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.
    Charbogne P; Kieffer BL; Befort K
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):204-17. PubMed ID: 24035914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
    Keck TM; John WS; Czoty PW; Nader MA; Newman AH
    J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Protective Effect of Social Reward on Opioid and Psychostimulant Reward and Relapse: Behavior, Pharmacology, and Brain Regions.
    Venniro M; Marino RAM; Chow JJ; Caprioli D; Epstein DH; Ramsey LA; Shaham Y
    J Neurosci; 2022 Dec; 42(50):9298-9314. PubMed ID: 36517252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of opioid-seeking reinstatement in the rat.
    Fattore L; Fadda P; Zanda MT; Fratta W
    Methods Mol Biol; 2015; 1230():295-307. PubMed ID: 25293336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Perspectives on Selective Dopamine D
    Newman AH; Xi ZX; Heidbreder C
    Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.
    Maguire DR; Gerak LR; Cami-Kobeci G; Husbands SM; France CP; Belli B; Flynn P
    J Pharmacol Exp Ther; 2020 Feb; 372(2):205-215. PubMed ID: 31748404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.
    Wee S; Koob GF
    Psychopharmacology (Berl); 2010 Jun; 210(2):121-35. PubMed ID: 20352414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of muscarinic receptors in alcohol and substance use disorders.
    Walker LC; Lawrence AJ
    Adv Pharmacol; 2020; 88():233-275. PubMed ID: 32416869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs.
    Cunha-Oliveira T; Rego AC; Oliveira CR
    Brain Res Rev; 2008 Jun; 58(1):192-208. PubMed ID: 18440072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm.
    Cordery SF; Taverner A; Ridzwan IE; Guy RH; Delgado-Charro MB; Husbands SM; Bailey CP
    Addict Biol; 2014 Jul; 19(4):575-86. PubMed ID: 23240906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kappa opioids as potential treatments for stimulant dependence.
    Prisinzano TE; Tidgewell K; Harding WW
    AAPS J; 2005 Oct; 7(3):E592-9. PubMed ID: 16353938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous opioids and addiction to alcohol and other drugs of abuse.
    Gianoulakis C
    Curr Top Med Chem; 2004; 4(1):39-50. PubMed ID: 14754375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.